Shots:
- AbbVie and Harvard University enter a $30M research alliance to study & develop novel therapies against emergent viral infections with an initial focus on coronavirus and the viruses leading to hemorrhagic fever
- The focus of the collaboration is to integrate fundamental biology into the pre/clinical development of new therapies for viral diseases
- AbbVie will deploy expertise and facilities to advance collaborative research and early-stage development efforts across five program addressing multiple therapeutic modalities: immunity and immunopathology, host targeting for antiviral therapies, antibody therapeutics, small molecules, and translational development
Click here to read full press release/ article | Ref: AbbVie | Image: RMIT University
